Development of Brain Targeting Peptide Based MMP-9 Inhibiting Nanoparticles for the Treatment of Brain Diseases with Elevated MMP-9 Activity.
Blood-brain-barrier
Brain drug delivery
MMP-9 inhibitor
Nanoparticles
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
20
04
2020
revised:
10
06
2020
accepted:
23
06
2020
pubmed:
6
7
2020
medline:
22
6
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
Latent and active levels of cerebral matrix metalloproteinase 9 (MMP-9) are elevated in neurological diseases and brain injuries, contributing to neurological damage and poor clinical outcomes. This study aimed developing peptide-based nanoparticles with ability to cross the blood-brain-barrier (BBB) and inhibit MMP-9. Three amphiphilic peptides were synthesised containing brain-targeting ligands (HAIYPRH or CKAPETALC) conjugated with MMP-9 inhibiting peptide (CTTHWGFTLC) linked by glycine (spacer) at the N-terminus, and the peptide sequences were conjugated at the N- terminus to cholesterol.
Identifiants
pubmed: 32621836
pii: S0022-3549(20)30354-3
doi: 10.1016/j.xphs.2020.06.021
pii:
doi:
Substances chimiques
Peptides
0
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3134-3144Informations de copyright
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.